|
1
|
Ferlay J, Colombet M, Soerjomataram I,
Mathers C, Parkin DM, Piñeros M, Znaor A and Bray F: Estimating the
global cancer incidence and mortality in 2018: GLOBOCAN sources and
methods. Int J cancer. 144:1941–1953. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Mehanna H, Beech T, Nicholson T, El-Hariry
I, McConkey C, Paleri V and Roberts S: Prevalence of human
papillomavirus in oropharyngeal and nonoropharyngeal head and neck
cancer-systematic review and meta-analysis of trends by time and
region. Head Neck. 35:747–755. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
De Virgilio A, Costantino A, Mercante G,
Pellini R, Ferreli F, Malvezzi L, Colombo G, Cugini G, Petruzzi G
and Spriano G: Transoral robotic surgery and intensity-modulated
radiotherapy in the treatment of the oropharyngeal carcinoma: A
systematic review and meta-analysis. Eur Arch Otorhinolaryngol.
278:1321–1335. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Visgauss JD, Eward WC and Brigman BE:
Innovations in intraoperative tumor visualization. Orthop Clin
North Am. 47:253–264. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Nguyen QT and Tsien RY:
Fluorescence-guided surgery with live molecular navigation-a new
cutting edge. Nat Rev Cancer. 13:653–662. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Gorphe P and Simon C: A systematic review
and meta-analysis of margins in transoral surgery for oropharyngeal
carcinoma. Oral Oncol. 98:69–77. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Boonstra MC, De Geus SWL, Prevoo HAJM,
Hawinkels LJAC, van de Velde CJH, Kuppen PJK, Vahrmeijer AL and
Sier CFM: Selecting targets for tumor imaging: An overview of
cancer–associated membrane proteins. Biomark Cancer. 8:119–133.
2016. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
van Oosten M, Crane LMA, Bart J, van
Leeuwen FW and van Dam GM: Selecting potential targetable
biomarkers for imaging purposes in colorectal cancer using target
selection criteria (TASC): A novel target identification tool.
Transl Oncol. 4:71–82. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Boonstra MC, van Driel PBAA, van Willigen
DM, Stammes MA, Prevoo HAJM, Tummers QRJG, Mazar AP, Beekman FJ,
Kuppen PJK, van de Velde CJH, et al: uPAR-targeted multimodal
tracer for pre- and intraoperative imaging in cancer surgery.
Oncotarget. 6:14260–14273. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Christensen A, Juhl K, Persson M, Charabi
BW, Mortensen J, Kiss K, Lelkaitis G, Rubek N, von Buchwald C and
Kjær A: uPAR-targeted optical near-infrared (NIR) fluorescence
imaging and PET for image-guided surgery in head and neck cancer:
Proof-of-concept in orthotopic xenograft model. Oncotarget.
8:15407–15419. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Nielsen CH, Jeppesen TE, Kristensen LK,
Jensen MM, Ali HHE, Madsen J, Wiinberg B, Petersen LC and Kjaer A:
PET imaging of tissue factor in pancreatic cancer using
64Cu-labeled active site-inhibited factor VII. J Nucl Med.
57:1112–1119. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
de Geus SWL, Baart VM, Boonstra MC, Kuppen
PJK, Prevoo HA, Mazar AP, Bonsing BA, Morreau H, van de Velde CJH,
Vahrmeijer AL and Sier CF: Prognostic impact of urokinase
plasminogen activator receptor expression in pancreatic cancer:
Malignant versus stromal cells. Biomark Insights.
12:11772719177154432017. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Boonstra MC, Verspaget HW, Ganesh S,
Kubben FJGM, Vahrmeijer AL, van de Velde CJH, Kuppen PJK, Quax PHA
and Sier CFM: Clinical applications of the urokinase receptor
(uPAR) for cancer patients. Curr Pharm Des. 17:1890–1910. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Noh H, Hong S and Huang S: Role of
urokinase receptor in tumor progression and development.
Theranostics. 3:487–495. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Hundsdorfer B, Zeilhofer HF, Bock KP,
Dettmar P, Schmitt M, Kolk A, Pautke C and Horch HH:
Tumour-associated urokinase-type plasminogen activator (uPA) and
its inhibitor PAI-1 in normal and neoplastic tissues of patients
with squamous cell cancer of the oral cavity-clinical relevance and
prognostic value. J Craniomaxillofac Surg. 33:191–196. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Bharadwaj AG, Holloway RW, Miller VA and
Waisman DM: Plasmin and plasminogen system in the tumor
microenvironment: Implications for cancer diagnosis, prognosis, and
therapy. Cancers (Basel). 13:18382021. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Madunić J: The urokinase plasminogen
activator system in human cancers: An overview of its prognostic
and predictive role. Thromb Haemost. 118:2020–2036. 2018.
View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Serpa MS, Mafra RP, Queiroz SIML, da Silva
LP, de Souza LB and Pinto LP: Expression of urokinase-type
plasminogen activator and its receptor in squamous cell carcinoma
of the oral tongue. Braz Oral Res. 32:e932018. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
van Keulen S, van den Berg NS, Nishio N,
Birkeland A, Zhou Q, Lu G, Wang HW, Middendorf L, Forouzanfar T,
Martin BA, et al: Rapid, non-invasive fluorescence margin
assessment: Optical specimen mapping in oral squamous cell
carcinoma. Oral Oncol. 88:58–65. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Weele EJT, Van Scheltinga AGT, Linssen MD,
Nagengast WB, Lindner I, Jorritsma-Smit A, de Vries EGE, Kosterink
JGW and Hooge MN: Development, preclinical safety, formulation, and
stability of clinical grade bevacizumab-800CW, a new near infrared
fluorescent imaging agent for first in human use. Eur J Pharm
Biopharm. 104:226–234. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Zaryouh H, De Pauw I, Baysal H, Peeters M,
Vermorken JB, Lardon F and Wouters A: Recent insights in the
PI3K/Akt pathway as a promising therapeutic target in combination
with EGFR-targeting agents to treat head and neck squamous cell
carcinoma. Med Res Rev. 42:112–155. 2022. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Beleva E and Grudeva-Popova J: From
Virchow's triad to metastasis: circulating hemostatic factors as
predictors of risk for metastasis in solid tumors. J BUON.
18:25–33. 2013.PubMed/NCBI
|
|
23
|
Han X, Guo B, Li Y and Zhu B: Tissue
factor in tumor microenvironment: A systematic review. J Hematol
Oncol. 7:542014. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Theunissen JW, Cai AG, Bhatti MM, Cooper
AB, Avery AD, Dorfman R, Guelman S, Levashova Z and Migone TS:
Treating tissue factor-positive cancers with antibody-drug
conjugates that do not affect blood clotting. Mol Cancer Ther.
17:2412–2426. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Zamani M, Grønhøj C, Jensen DH, Carlander
AF, Agander T, Kiss K, Olsen C, Baandrup L, Nielsen FC, Andersen E,
et al: The current epidemic of HPV-associated oropharyngeal cancer:
An 18-year Danish population-based study with 2,169 patients. Eur J
Cancer. 134:52–59. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Brierley JD, Gospodarowicz MK and
Wittekind C: TNM classification of malignant tumours. 8th edition.
Wiley Blackwell; 2017
|
|
27
|
Allred DC, Harvey JM, Berardo M and Clark
GM: Prognostic and predictive factors in breast cancer by
immunohistochemical analysis. Mod Pathol. 11:155–168.
1998.PubMed/NCBI
|
|
28
|
Bossi P, Resteghini C, Paielli N, Licitra
L, Pilotti S and Perrone F: Prognostic and predictive value of EGFR
in head and neck squamous cell carcinoma. Oncotarget.
7:74362–74379. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Preuss SF, Weinell A, Molitor M, Semrau R,
Stenner M, Drebber U, Wedemeyer I, Hoffmann TK, Guntinas-Lichius O
and Klussmann JP: Survivin and epidermal growth factor receptor
expression in surgically treated oropharyngeal squamous cell
carcinoma. Head Neck. 30:1318–1324. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Chandarana SP, Lee JS, Chanowski EJP,
Sacco AG, Bradford CR, Wolf GT, Prince ME, Moyer JS, Eisbruch A,
Worden FP, et al: Prevalence and predictive role of p16 and
epidermal growth factor receptor in surgically treated
oropharyngeal and oral cavity cancer. Head Neck. 35:1083–1090.
2013. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Christensen A, Kiss K, Lelkaitis G, Juhl
K, Persson M, Charabi BW, Mortensen J, Forman JL, Sørensen AL,
Jensen DH, et al: Urokinase-type plasminogen activator receptor
(uPAR), tissue factor (TF) and epidermal growth factor receptor
(EGFR): Tumor expression patterns and prognostic value in oral
cancer. BMC Cancer. 17:5722017. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Gao RW, Teraphongphom NT, van den Berg NS,
Martin BA, Oberhelman NJ, Divi V, Kaplan MJ, Hong SS, Lu G, Ertsey
R, et al: Determination of tumor margins with surgical specimen
mapping using near-infrared fluorescence. Cancer Res. 78:5144–5154.
2018. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Baart VM, van Duijn C, van Egmond SL,
Dijckmeester WA, Jansen JC, Vahrmeijer AL, Sier CFM and Cohen D:
EGFR and αvβ6 as promising targets for molecular imaging of
cutaneous and mucosal squamous cell carcinoma of the head and neck
region. Cancers (Basel). 12:14742020. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
de Boer E, Warram JM, Tucker MD, Hartman
YE, Moore LS, de Jong JS, Chung TK, Korb ML, Zinn KR, van Dam GM,
et al: In vivo fluorescence immunohistochemistry: Localization of
fluorescently labeled cetuximab in squamous cell carcinomas. Sci
Rep. 5:101692015. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Voskuil FJ, de Jongh SJ, Hooghiemstra WTR,
Linssen MD, Steinkamp PJ, de Visscher SAHJ, Schepman KP, Elias SG,
Meersma GJ, Jonker PKC, et al: Fluorescence-guided imaging for
resection margin evaluation in head and neck cancer patients using
cetuximab-800CW: A quantitative dose-escalation study.
Theranostics. 10:3994–4005. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Cramer JD, Burtness B and Ferris RL:
Immunotherapy for head and neck cancer: Recent advances and future
directions. Oral Oncol. 99:1044602019. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Wojtukiewicz MZ, Sierko E, Zacharski LR,
Rózanska-Kudelska M and Zimnoch L: Occurrence of components of
fibrinolytic pathways in situ in laryngeal cancer. Semin Thromb
Hemost. 29:317–320. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Bacchiocchi R, Rubini C, Pierpaoli E,
Borghetti G, Procacci P, Nocini PF, Santarelli A, Rocchetti R,
Ciavarella D, Lo Muzio L and Fazioli F: Prognostic value analysis
of urokinase-type plasminogen activator receptor in oral squamous
cell carcinoma: An immunohistochemical study. BMC Cancer.
8:2202008. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
van der Waal I: Potentially malignant
disorders of the oral and oropharyngeal mucosa; terminology,
classification and present concepts of management. Oral Oncol.
45:317–323. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Curino A, Patel V, Nielsen BS, Iskander
AJ, Ensley JF, Yoo GH, Holsinger FC, Myers JN, El-Nagaar A, Kellman
RM, et al: Detection of plasminogen activators in oral cancer by
laser capture microdissection combined with zymography. Oral Oncol.
40:1026–1032. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Lechien JR, Seminerio I, Descamps G, Mat
Q, Mouawad F, Hans S, Julieron M, Dequanter D, Vanderhaegen T,
Journe F and Saussez S: Impact of HPV infection on the immune
system in oropharyngeal and non-oropharyngeal squamous cell
carcinoma: A systematic review. Cells. 8:10612019. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Subbarayan RS, Arnold L, Gomez JP and
Thomas SM: The role of the innate and adaptive immune response in
HPV-associated oropharyngeal squamous cell carcinoma. Laryngoscope
Investig Otolaryngol. 4:508–512. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Gonias SL and Zampieri C: Plasminogen
receptors in human malignancies: Effects on prognosis and
feasibility as targets for drug development. Curr Drug Targets.
21:647–656. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Magnussen S, Rikardsen OG, Hadler-Olsen E,
Uhlin-Hansen L, Steigen SE and Svineng G: Urokinase plasminogen
activator receptor (uPAR) and plasminogen activator inhibitor-1
(PAI-1) are potential predictive biomarkers in early stage oral
squamous cell carcinomas (OSCC). PLoS One. 9:e1018952014.
View Article : Google Scholar : PubMed/NCBI
|
